Mineralys Therapeutics (MLYS) Net Equity Issued and Repurchased (2022 - 2026)

Mineralys Therapeutics has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $188.9 million in Q2 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $188.9 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $188.9 million (changed N/A YoY) and the FY2025 annual result came in at $188.9 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased grew to $188.9 million in Q2 2025 per MLYS's latest filing, from -$203.0 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $203.6 million in Q1 2023 and troughed at -$203.0 million in Q4 2023.
• A 3-year average of $51.1 million and a median of $58.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 271.71% in 2023, down 271.71% in 2023.
• Over 3 years, Net Equity Issued and Repurchased stood at $118.2 million in 2022, then slumped by 271.71% to -$203.0 million in 2023, then soared by 193.05% to $188.9 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $188.9 million, -$203.0 million, and -$581000.0 for Q2 2025, Q4 2023, and Q2 2023 respectively.